# A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer

> **NCT04400188** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Fluzoparib
- **DRUG:** temozolomide
- **BIOLOGICAL:** SHR-1316

## Key facts

- **NCT ID:** NCT04400188
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-11
- **Primary completion:** 2022-01-15
- **Final completion:** 2022-01-15
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04400188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04400188, "A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04400188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*